Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;70(5):890-902.
doi: 10.1002/mus.28224. Epub 2024 Aug 11.

Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review

Katie O'Brien  1   2 , Kay Nguo  1 , Eppie M Yiu  3   4   5 , Ian R Woodcock  3   4   5 , Natassja Billich  6   7 , Zoe E Davidson  1   3   4
Affiliations

Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review

Katie O'Brien et al. Muscle Nerve. 2024 Nov.

Abstract

The nutritional implications of spinal muscular atrophy (SMA) are profound. Disease modifying therapies (DMT) have improved clinical outcomes. This review describes the impact of DMT on nutrition outcomes. A systematic search strategy was applied across seven databases until May 2023. Eligible studies measured nutrition outcomes in individuals with SMA on DMT (nusinersen, risdiplam or onasemnogene abeparvovec [OA]) compared to untreated comparators. Nutrition outcomes included anthropometry, feeding route, swallowing dysfunction, dietary intake, dietetic intervention, nutritional biochemistry, metabolism, gastrointestinal issues and energy expenditure. Articles retrieved were screened in duplicate, data were extracted and appraised systematically. Sixty three articles from 54 studies were included; 41% (n = 22) investigated nusinersen in pediatric participants with SMA type 1. Anthropometry (n = 18), feeding route (n = 39), and swallowing dysfunction (n = 18) were the most commonly reported outcomes. In combined pediatric and adult cohorts, BMI z-score remained stable post nusinersen therapy. The proportion of children with SMA requiring enteral nutrition was stable post nusinersen therapy. Ability to thrive at age 1.5 years was higher in children treated in early infancy with OA compared to historical controls. Significant heterogeneity existed across study population characteristics and outcome measures. Nusinersen may prevent deterioration in some nutrition outcomes; and OA in early infancy may be associated with improved nutrition outcomes. Timing of DMT initiation is an important consideration for future nutrition research. Studies investigating nutrition as a primary outcome of DMT, using consistent outcome measures are required for nutritional management strategies for this cohort to be appropriately tailored.

Keywords: SMA; disease modifying therapy; nutrition; spinal muscular atrophy; systematic review.

PubMed Disclaimer

References

REFERENCES

    1. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy‐determining gene. Cell. 1995;80(1):155‐165.
    1. Lunn MRBS, Wang CHD. Spinal muscular atrophy. Lancet. 2008;371(9630):2120‐2133.
    1. Prior TW. Spinal muscular atrophy diagnostics. J Child Neurol. 2007;22(8):952‐956.
    1. Prior TW, Leach ME, Finanger E. Spinal muscular atrophy. In: Adam MP, Everman DB, Mirzaa GM, et al., eds. GeneReviews [Internet]. University of Washington; 2000. https://www.ncbi.nlm.nih.gov/books/NBK1352/ Updated December 3, 2020. Accessed March 6, 2023. Mar 6.
    1. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027‐1049.

Publication types

MeSH terms

LinkOut - more resources